Wise R, Andrews J M
Department of Medical Microbiology, City Hospital NHS Trust, Birmingham, UK.
J Antimicrob Chemother. 1997 Dec;40 Suppl A:27-30. doi: 10.1093/jac/40.suppl_1.27.
The in-vitro activity of grepafloxacin was compared with that of other antimicrobials against respiratory tract pathogens collected from 15 UK laboratories over the winter of 1995-96. Penicillin-resistant Streptococcus pneumoniae was not encountered, but macrolide resistance was seen in approximately 10% of strains. Grepafloxacin (MIC90 0.25 mg/L) was four- to eight-fold more active than ciprofloxacin. Twelve percent of Haemophilus influenzae were beta-lactamase producers, macrolides were relatively inactive yet fluoroquinolones were highly active. Moraxella catarrhalis were highly susceptible to fluoroquinolones and macrolides. The activity of grepafloxacin against respiratory tract pathogens should make it a useful agent in the treatment of infections at this site.
1995 - 1996年冬季，从英国15个实验室收集呼吸道病原体，比较了格帕沙星与其他抗菌药物的体外活性。未发现对青霉素耐药的肺炎链球菌，但约10%的菌株对大环内酯类耐药。格帕沙星（MIC90为0.25mg/L）的活性比环丙沙星高4至8倍。12%的流感嗜血杆菌产β-内酰胺酶，大环内酯类相对无活性而氟喹诺酮类高度活性。卡他莫拉菌对氟喹诺酮类和大环内酯类高度敏感。格帕沙星对呼吸道病原体的活性使其成为治疗该部位感染的有用药物。
